Shannon Chang

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

Fábio M. Iwamoto, Kathleen R. Lamborn, H. I. Robins et al. · Neuro-Oncology · 2010 · 219 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Patrick Y. Wen, Shannon Chang, Kathleen R. Lamborn et al. · Neuro-Oncology · 2014 · 167 citations · Full text

Medicine, Oncology, Pharmacology +16

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Jennifer Clarke, M. M. Ennis, W. K. Alfred Yung et al. · Neuro-Oncology · 2011 · 118 citations · Full text

Medicine, Oncology, Surgery +17

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Wenting Wu, Kathleen R. Lamborn, Jan C. Buckner et al. · Neuro-Oncology · 2009 · 102 citations · Full text

Medicine, Oncology, Neuro-oncology +16

Phase II study of paclitaxel in patients with recurrent malignant glioma.

Michael D. Prados, S. Clifford Schold, Alexander M. Spence et al. · Journal of Clinical Oncology · 1996 · 95 citations

Medicine, Oncology, Pharmacology +17